|
|
Post by mnkdfann on Jun 8, 2019 8:22:33 GMT -5
Y'all will love this story, I just know it. (In case it is not obvious to some, the above is sarcasm. In truth, I suspect many people will be upset / frustrated with what the article reports.) www.diabetesforecast.org/2019/02-mar-apr/ultra-rapid-acting-insulin.htmlYet even though drug manufacturers have been making various insulin formulations for more than a century, science still hasn’t found a way to produce formulas that supply insulin to the body in a way that matches—or at least very closely mimics—what happens in the healthy human body. That’s why the American Diabetes Association has given Appel a grant to help him engineer an ultra-rapid-acting insulin that starts working faster and, as a result, disappears from the bloodstream faster, too—all while remaining even more stable preinjection than state-of-the-art insulins on the market today. “If you were to have an insulin with faster onset as well as a much shorter [duration], it could be really beneficial,” says Appel. [Apologies if someone posted this previously; if so, I think I missed it.] |
|
|
|
Post by goyocafe on Jun 8, 2019 9:09:56 GMT -5
Unbelievable. What’s going on?
|
|
|
|
Post by celo on Jun 8, 2019 9:16:41 GMT -5
"But insulin formulations face artificial conditions. For starters, they have to be kept in a form that’s chemically stable so they don’t break down during prolonged storage. Then they must be administered by injection into the skin instead of by direct secretion from the pancreas into the bloodstream.
Stabilizing agents, mainly the inactive chemical zinc, keep insulin from deteriorating while it’s stored on the pharmacy shelf. But they can also affect the absorption of the drug: Injected insulin appears in the bloodstream at a slower rate than insulin that’s secreted directly from the pancreas. This, in turn, leads to insulin lingering in the body longer than it normally would."
It would be great to find an insulin that wouldn't breakdown when being stored. It would be incredibly freaking awesome to find a product that didn't have Zinc or deteriorate over time. ADA is corrupt.
|
|
|
|
Post by mango on Jun 8, 2019 11:20:36 GMT -5
"But insulin formulations face artificial conditions. For starters, they have to be kept in a form that’s chemically stable so they don’t break down during prolonged storage. Then they must be administered by injection into the skin instead of by direct secretion from the pancreas into the bloodstream. Stabilizing agents, mainly the inactive chemical zinc, keep insulin from deteriorating while it’s stored on the pharmacy shelf. But they can also affect the absorption of the drug: Injected insulin appears in the bloodstream at a slower rate than insulin that’s secreted directly from the pancreas. This, in turn, leads to insulin lingering in the body longer than it normally would." It would be great to find an insulin that wouldn't breakdown when being stored. It would be incredibly freaking awesome to find a product that didn't have Zinc or deteriorate over time. ADA is corrupt. Afrezza is zinc-free |
|
|
|
Post by peppy on Jun 8, 2019 11:31:16 GMT -5
"But insulin formulations face artificial conditions. For starters, they have to be kept in a form that’s chemically stable so they don’t break down during prolonged storage. Then they must be administered by injection into the skin instead of by direct secretion from the pancreas into the bloodstream. Stabilizing agents, mainly the inactive chemical zinc, keep insulin from deteriorating while it’s stored on the pharmacy shelf. But they can also affect the absorption of the drug: Injected insulin appears in the bloodstream at a slower rate than insulin that’s secreted directly from the pancreas. This, in turn, leads to insulin lingering in the body longer than it normally would." It would be great to find an insulin that wouldn't breakdown when being stored. It would be incredibly freaking awesome to find a product that didn't have Zinc or deteriorate over time. ADA is corrupt. Is it Mango? HUMALOG is a sterile, aqueous, clear, and colorless solution. Each milliliter of HUMALOG contains insulin lispro 100 units, 16 mg glycerin, 1.88 mg dibasic sodium phosphate, 3.15 mg Metacresol, zinc oxide content adjusted to provide 0.0197 mg zinc ion, trace amounts of phenol, and Water for Injection. Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid 10% and/or sodium hydroxide 10%. HUMULIN® R REGULAR INSULIN HUMAN INJECTION, USP, (rDNA ORIGIN) 100 UNITS PER ML (U-100) DESCRIPTION R U-100 is a polypeptide hormone structurally identical to human insulin synthesized through rDNA technology in a special non-disease-producing laboratory strain of Escherichia coli bacteria. Humulin R U-100 has the empirical formula C257H383N65O77S6 and a molecular weight of 5808. Humulin R U-100 is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerin 16 mg/mL and metacresol 2.5 mg/mL, endogenous zinc (approximately 0.015 mg/100 units) and water for injection. The pH is 7.0 to 7.8. Sodium hydroxide and/or hydrochloric acid may be added during manufacture to adjust the pH. Are you saying afrezza is not in solution so no "glycerin 16 mg/mL and metacresol 2.5 mg/mL, endogenous zinc (approximately 0.015 mg/100 units) and water for injection." ? |
|
|
|
Post by mango on Jun 8, 2019 11:46:29 GMT -5
Is it Mango? HUMALOG is a sterile, aqueous, clear, and colorless solution. Each milliliter of HUMALOG contains insulin lispro 100 units, 16 mg glycerin, 1.88 mg dibasic sodium phosphate, 3.15 mg Metacresol, zinc oxide content adjusted to provide 0.0197 mg zinc ion, trace amounts of phenol, and Water for Injection. Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid 10% and/or sodium hydroxide 10%. HUMULIN® R REGULAR INSULIN HUMAN INJECTION, USP, (rDNA ORIGIN) 100 UNITS PER ML (U-100) DESCRIPTION R U-100 is a polypeptide hormone structurally identical to human insulin synthesized through rDNA technology in a special non-disease-producing laboratory strain of Escherichia coli bacteria. Humulin R U-100 has the empirical formula C257H383N65O77S6 and a molecular weight of 5808. Humulin R U-100 is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerin 16 mg/mL and metacresol 2.5 mg/mL, endogenous zinc (approximately 0.015 mg/100 units) and water for injection. The pH is 7.0 to 7.8. Sodium hydroxide and/or hydrochloric acid may be added during manufacture to adjust the pH. Are you saying afrezza is not in solution so no "glycerin 16 mg/mL and metacresol 2.5 mg/mL, endogenous zinc (approximately 0.015 mg/100 units) and water for injection." ?The zinc is washed off the insulin molecules prior to coupling with FDKP—the molecular entanglement |
|
|
|
Post by goyocafe on Jun 8, 2019 12:56:39 GMT -5
Is it Mango? HUMALOG is a sterile, aqueous, clear, and colorless solution. Each milliliter of HUMALOG contains insulin lispro 100 units, 16 mg glycerin, 1.88 mg dibasic sodium phosphate, 3.15 mg Metacresol, zinc oxide content adjusted to provide 0.0197 mg zinc ion, trace amounts of phenol, and Water for Injection. Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid 10% and/or sodium hydroxide 10%. HUMULIN® R REGULAR INSULIN HUMAN INJECTION, USP, (rDNA ORIGIN) 100 UNITS PER ML (U-100) DESCRIPTION R U-100 is a polypeptide hormone structurally identical to human insulin synthesized through rDNA technology in a special non-disease-producing laboratory strain of Escherichia coli bacteria. Humulin R U-100 has the empirical formula C257H383N65O77S6 and a molecular weight of 5808. Humulin R U-100 is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerin 16 mg/mL and metacresol 2.5 mg/mL, endogenous zinc (approximately 0.015 mg/100 units) and water for injection. The pH is 7.0 to 7.8. Sodium hydroxide and/or hydrochloric acid may be added during manufacture to adjust the pH. Are you saying afrezza is not in solution so no "glycerin 16 mg/mL and metacresol 2.5 mg/mL, endogenous zinc (approximately 0.015 mg/100 units) and water for injection." ?I don't see "zinc" as the focus of this article. The ADA is in search of an ultra-fast acting insulin (and funding that research) because they see the potential it holds for helping PWDs. in which case, it begs to ask why they refuse to acknowledge Afrezza for the science it represents in this arena? It's almost like they don't want to believe it or are trying to ignore the obvious. |
|
|
|
Post by peppy on Jun 8, 2019 13:16:06 GMT -5
Is it Mango? HUMALOG is a sterile, aqueous, clear, and colorless solution. Each milliliter of HUMALOG contains insulin lispro 100 units, 16 mg glycerin, 1.88 mg dibasic sodium phosphate, 3.15 mg Metacresol, zinc oxide content adjusted to provide 0.0197 mg zinc ion, trace amounts of phenol, and Water for Injection. Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid 10% and/or sodium hydroxide 10%. HUMULIN® R REGULAR INSULIN HUMAN INJECTION, USP, (rDNA ORIGIN) 100 UNITS PER ML (U-100) DESCRIPTION R U-100 is a polypeptide hormone structurally identical to human insulin synthesized through rDNA technology in a special non-disease-producing laboratory strain of Escherichia coli bacteria. Humulin R U-100 has the empirical formula C257H383N65O77S6 and a molecular weight of 5808. Humulin R U-100 is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerin 16 mg/mL and metacresol 2.5 mg/mL, endogenous zinc (approximately 0.015 mg/100 units) and water for injection. The pH is 7.0 to 7.8. Sodium hydroxide and/or hydrochloric acid may be added during manufacture to adjust the pH. Are you saying afrezza is not in solution so no "glycerin 16 mg/mL and metacresol 2.5 mg/mL, endogenous zinc (approximately 0.015 mg/100 units) and water for injection." ?I don't see "zinc" as the focus of this article. The ADA is in search of an ultra-fast acting insulin (and funding that research) because they see the potential it holds for helping PWDs. in which case, it begs to ask why they refuse to acknowledge Afrezza for the science it represents in this arena? It's almost like they don't want to believe it or are trying to ignore the obvious. Quote: The ADA is in search of an ultra-fast acting insulin (and funding that research) because they see the potential it holds for helping PWDs. Reply: that is not going to happen with subq. Subcutaneous tissue has few blood vessels and so drugs injected here are for slow, sustained rates of absorption.[3] It is slower than intramuscular injections but still faster than intradermal injections.[3] They tried adding niacin. www.screencast.com/t/PEg65lsi9W2F |
|
|
|
Post by mytakeonit on Jun 8, 2019 14:24:04 GMT -5
So on April 1st Appel said "I found the solution ... it is called Afrezza." And pockets the $$$. Obviously, the ADA was P'Oed that Dr. Kendall left and went to Mannkind.
But, that's mytakeonit
|
|
|
|
Post by mnkdfann on Jun 8, 2019 15:09:55 GMT -5
So on April 1st Appel said "I found the solution ... it is called Afrezza." And pockets the $$$. Obviously, the ADA was P'Oed that Dr. Kendall left and went to Mannkind. Well, if only. More like, Kendall left the ADA, and no one else left there knows much or cares much about Afrezza. |
|
|
|
Post by mnkdfann on Jun 8, 2019 15:12:44 GMT -5
sdrc.stanford.edu/eric-appel"The Appel lab at Stanford integrates concepts and approaches from supramolecular chemistry and natural/synthetic materials to tackle healthcare challenges of critical importance to society, including diabetes mellitus. They have developed a platform of materials with unique, tunable, and stimuli-responsive properties that they are exploiting as the basis for novel treatment strategies for a range of disease targets. Relevant to diabetes, Appel’s group has developed “smart” excipient technology affording unprecedented stabilization of monomeric insulin, a strategy that forms the basis of novel ultra-fast-acting insulin formulations for treatment of diabetes. They have several on-going collaborations with multiple members of the Stanford DRC that focus on the translation of their new material technologies."
|
|
|
|
Post by goyocafe on Jun 8, 2019 17:03:47 GMT -5
I don't see "zinc" as the focus of this article. The ADA is in search of an ultra-fast acting insulin (and funding that research) because they see the potential it holds for helping PWDs. in which case, it begs to ask why they refuse to acknowledge Afrezza for the science it represents in this arena? It's almost like they don't want to believe it or are trying to ignore the obvious. Quote: The ADA is in search of an ultra-fast acting insulin (and funding that research) because they see the potential it holds for helping PWDs. Reply: that is not going to happen with subq. Subcutaneous tissue has few blood vessels and so drugs injected here are for slow, sustained rates of absorption.[3] It is slower than intramuscular injections but still faster than intradermal injections.[3] They tried adding niacin. www.screencast.com/t/PEg65lsi9W2FIf you and I recognize the limitations of subq injections of a ultra-rapid acting insulin, why does the ADA seem to insist on funding further research and ignore the opportunity right in front of it to help PWDs today? Any new drug using PEG or other means of changing the route or method of administration is years away. Afrezza is sitting on a cold shelf in your pharmacy today. Someone has to call the ADA out on this. I can't believe those in charge of Afrezza and those at the helm of all the various diabetes organizations are so mum on this issue. |
|
|
|
Post by mango on Jun 8, 2019 17:28:54 GMT -5
Quote: The ADA is in search of an ultra-fast acting insulin (and funding that research) because they see the potential it holds for helping PWDs. Reply: that is not going to happen with subq. Subcutaneous tissue has few blood vessels and so drugs injected here are for slow, sustained rates of absorption.[3] It is slower than intramuscular injections but still faster than intradermal injections.[3] They tried adding niacin. www.screencast.com/t/PEg65lsi9W2FIf you and I recognize the limitations of subq injections of a ultra-rapid acting insulin, why does the ADA seem to insist on funding further research and ignore the opportunity right in front of it to help PWDs today? Any new drug using PEG or other means of changing the route or method of administration is years away. Afrezza is sitting on a cold shelf in your pharmacy today. Someone has to call the ADA out on this. I can't believe those in charge of Afrezza and those at the helm of all the various diabetes organizations are so mum on this issue. The answer is simple and is staring you, us all, in the face. ADA = The Insulin Cartel |
|
|
|
Post by agedhippie on Jun 8, 2019 21:20:06 GMT -5
Quote: The ADA is in search of an ultra-fast acting insulin (and funding that research) because they see the potential it holds for helping PWDs. Reply: that is not going to happen with subq. Subcutaneous tissue has few blood vessels and so drugs injected here are for slow, sustained rates of absorption.[3] It is slower than intramuscular injections but still faster than intradermal injections.[3] They tried adding niacin. www.screencast.com/t/PEg65lsi9W2FIf you and I recognize the limitations of subq injections of a ultra-rapid acting insulin, why does the ADA seem to insist on funding further research and ignore the opportunity right in front of it to help PWDs today? Any new drug using PEG or other means of changing the route or method of administration is years away. Afrezza is sitting on a cold shelf in your pharmacy today. Someone has to call the ADA out on this. I can't believe those in charge of Afrezza and those at the helm of all the various diabetes organizations are so mum on this issue. It's all about the artificial pancreas. URLi and FIASP have less than ideal profiles for a rapid in/rapid out insulin, and Afrezza is a non-starter because you cannot automatically dispense it, so the ADA is funding research into a rapid in/rapid out pumpable insulin. |
|
|
|
Post by longliner on Jun 8, 2019 23:08:07 GMT -5
$$$
|
|
